OR WAIT null SECS
Cognizant as part of its collaboration with TransCelerate BioPharma Inc., a non-profit organization with membership comprised of global biopharmaceutical companies, announced new Shared Investigator Platform (SIP) capabilities for clinical trial researchers to access, share, and analyze data.
SIP is a multi-tenanted, cloud-based, open architecture collaboration platform to support common research and clinical trial requirements for the biopharmaceutical industry. It brings together technologies to streamline collaboration and offer a centralized point of access for trial sponsors, CROs, investigators, clinical researchers and ultimately regulators. By converging the work of multiple stakeholders, the SIP helps reduce the risks and complexity of clinical development, to improve efficiency.
Cognizant and TransCelerate BioPharma will be demonstrating the platform's capabilities at DIA 2017, the Drug Information Association's annual meeting, this week June 18-22 at McCormick Place in Chicago, IL. Cognizant’s Booth # is 1043. Cognizant and TransCelerate BioPharma will present at the Innovation Theater Showcase on Wednesday, June 21 at 12 noon.
"The Shared Investigator Platform is a critical initiative for TransCelerate and our membership. Since we launched it in 2016, some of our members are already experiencing the benefits of a single platform and we continue to collaborate closely with Cognizant and other partners to deliver enhanced usability and functionality throughout 2017," said, Dalvir Gill, PhD, CEO TransCelerate. "The SIP is a transformative technology that benefits researchers by simplifying processes and reducing time and effort spent on common study activities."
"We are excited about our ongoing collaboration with TransCelerate, its member companies and other partners to enhance this industry first initiative, which focuses on significantly simplifying, streamlining and transforming clinical development through greater stakeholder collaboration and communication. Our focus has been on building a robust, scalable and open architecture platform and to enable continuous innovation by leveraging and incorporating new solutions and technologies from an eco-system of partners. Through this, we are making the whole experience easier for investigators so that they can focus on science and patient care," said Bhaskar Sambasivan, Senior Vice President and Global Head of Life Sciences Markets at Cognizant.
Additional information on the capabilities of the Shared Investigator Platform can be found here:
Learn More About Cognizant's Healthcare and Life Sciences Practice